Neurotherapeutics in the Era of Translational Medicine is an Elsevier publication edited by Richard A. Smith, Brian K. Kaspar, and Clive N. Svendsen. This anthology provides a comprehensive review on the progress of translational research in neurotherapeutics for neurologic disorders.
Table of Contents
Development of a molecular therapy for the SOD1 familial variant of ALS
Unraveling molecular biology of C9ORF72 repeat expansions in amyotrophic lateral sclerosis-frontotemporal dementia: Implications for therapy
Translating molecular therapies for spinal muscular atrophy
From uncovering the mechanism of transthyretin aggregation to the drug tafamidis for ameliorating neurodegeneration and cardiomyopathy
A novel treatment for Parkinson's disease and ALS: Combined cell and gene therapies
Parkinson's disease: Genetic-driven therapeutic approaches
Neural stem cell-mediated brain tumor therapy
Advances in migraine therapeutics: The role of calcitonin gene-related peptide
The impact of translational research on the development of therapeutic agents for multiple sclerosis
Advances in treating myasthenia gravis
The endocannabinoid system as a target for the treatment of neurological disorders
Identification of biomarkers for diagnosing and monitoring therapy in the treatment of neurologic disorders
3D Alzheimer's disease in a dish: Implications for drug discovery
Improving clinical trial efficiency with machine learning models of disease progression
Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development
Repurposing FDA-approved pharmaceuticals: The development of Nuedexta
Bioethics in the era of translational medicine
Government efforts to promote the development of neurotherapeutics for the treatment of neurological diseases
Innovative funding models for neurotherapeutics